Abstract:
The present study aims to determine the effects of genistein on H. pylori growth and gastritis in rats. Male Sprague-Dawley rats were randomly divided into three groups including control group, H. pylori infection group and genistein treatment group. H. pylori infection group and genistein treatment groups were 3 day pre-treatment with streptomycin (5 mg/mL) and inoculated with H. pylori suspension (108-10 CFU/ml; 1 ml/rat, b.i.d.) for 3 consecutive days. Then, in the rats of genistein treatment group were treated with genistein (16 mg/kg BW b.i.d.) for 14 days. On the last day of experimental protocol, serum samples were collected to measure TNF-α level and CINC-1 level. The stomach were removed for H. pylori detection by urease test, gastric MDA level and pathological examination. Furthermore, the anti-H. pylori activity of genistein were investigated at concentrations of 0.25, 0.5, 1, 1.5, 2 and 4 M by using disc diffusion method. In vivo showed H. pylori infection group had significantly higher levels of serum TNF- α and CINC-1 than control group (43.50 ± 16.51 pg/ml vs. 20.89 ± 8.90 pg/ml, 138.10 ±43.56 pg/ml vs. 81.27 ± 19.89 pg/ml, P<0.05, respectively). In genistein treatment group had significantly lower levels of serum TNF-α and CINC-1 than in H. pylori infection group (29.33 ± 10.77 pg/ml vs. 43.50 ± 16.51 pg/ml, 103.25 ± 23.76 pg/ml vs. 138.10 ± 43.56 pg/ml, P<0.05, respectively). This study showed no significant change in gastric MDA levels in each group. In vitro study showed the growth of H. pylori was not inhibited by the various concentrations of genistein. In conclusion, these observations suggested that administration of genistein could attenuate H. pylori-induced gastritis, possibly by reducing inflammatory mediators and improve gastric pathology.
